Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) Director Nassim Usman sold 3,452 shares of the stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $12.00, for a total transaction of $41,424.00. Following the completion of the sale, the director now owns 1,636 shares of the company’s stock, valued at approximately $19,632. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Nassim Usman also recently made the following trade(s):
- On Wednesday, May 1st, Nassim Usman sold 20,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $14.13, for a total transaction of $282,600.00.
Gyre Therapeutics Stock Performance
Gyre Therapeutics stock opened at $12.04 on Tuesday. The firm’s fifty day simple moving average is $12.78 and its 200-day simple moving average is $16.74. Gyre Therapeutics, Inc. has a 1-year low of $4.80 and a 1-year high of $30.40.
Gyre Therapeutics Company Profile
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Featured Stories
- Five stocks we like better than Gyre Therapeutics
- Most active stocks: Dollar volume vs share volume
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Are Penny Stocks a Good Fit for Your Portfolio?
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.